CHEK2 1100delC mutation in Russian ovarian cancer patients

Hereditary Cancer in Clinical Practice

Volumn 5, Issue 3, 2007, Pages 153-156

  Krylova, Nadezhda Yu ^a   Ponomariova, Daria N ^b   Sherina, Natalia Yu ^b   Ogorodnikova, Natalia Yu ^b   Logvinov, Denis A ^b   Porhanova, Natalia V ^c   Lobeiko, Oksana S ^b   Urmoncheyeva, Adel F ^a   Maximov, Sergey Ya ^b   Togo, Alexandr V ^b   Suspitsin, Evgeny N ^b,d   Imyanitov, Evgeny N ^a,b,d  

^a NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^b N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^c Regional Oncological Hospital   (Russian Federation)

^d SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

BRCA1; BRCA2; Ovarian cancer; Screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; OVARY CANCER; PATHOGENESIS; RUSSIAN FEDERATION;

EID: 35348849467     PISSN: 17312302     EISSN: None     Source Type: Journal    
DOI: 10.1186/1897-4287-5-3-153     Document Type: Article

References (12)

1. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676.
2. Sowter HM, Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 2005; 26: 1651-1656.
3. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR; CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-59.
4. CHEK2 Breast Cancer Case-Control Consortium. CHEK2* 1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004; 74: 1175-1182.
5. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006; 25: 5912-5919.
6. Baysal BE, DeLoia JA, Willett-Brozick JE, Goodman MT, Brady MF, Modugno F, Lynch HT, Conley YP, Watson P, Gallion HH. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol 2004; 95: 62-69.
7. Szymanska-Pasternak J, Szymanska A, Medrek K, Imyanitov EN, Cybulski C, Gorski B, Magnowski P, Dziuba I, Gugala K, Debniak B, Gozdz S, Sokolenko AP, Krylova NY, Lobeiko OS, Narod SA, Lubinski J. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 2006; 102: 429-431.
8. Chekmariova EV, Sokolenko AP, Buslov KG, Iyevleva AG, Ulibina YM, Rozanov ME, Mitiushkina NV, Togo AV, Matsko DE, Voskresenskiy DA, Chagunava OL, Devilee P, Cornelisse C, Semiglazov VF, Imyanitov EN. CHEK2 1100delC mutation is frequent among Russian breast cancer patients. Breast Cancer Res Treat 2006; 100: 99-102.
9. Buslov KG, Iyevleva AG, Chekmariova EV, Suspitsin EN, Togo AV, Kuligina ESh, Sokolenko AP, Matsko DE, Turkevich EA, Lazareva YR, Chagunava OL, Bit-Sava EM, Semiglazov VF, Devilee P, Cornelisse C, Hanson KP, Imyanitov EN. NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. Int J Cancer 2005; 114: 585-589.
10. Malander S, Riddemeim M, Måsbäck A, Loman N, Kristoffersson U, Olsson H, Nilbert M, Borg A. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer 2004; 40: 422-428.
11. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104: 2807-2816.
12. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25: 5864-5874.